Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

What Is the Evidence That Tumors Are Angiogenesis Dependent?

Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509 · see citing works

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · see citing works

Thomas, Springfield, Illinois

MAGOUN, H. N. (1965) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196504000-00011 · Cited by 2,931 · see citing works

Clinical Applications of Research on Angiogenesis

Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,242 · see citing works

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,870 · see citing works

Angiostatin induces and sustains dormancy of human primary tumors in mice

O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170 · see citing works

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents

Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441 · see citing works

Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.

Singh, R. K., Gutman, M., BUCANA, C. D., Sanchez, R. R., Llansa, N., & Fidler, I. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4562 · Cited by 437 · see citing works

Tumor angiogenesis and tissue factor

Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0296-167 · Cited by 295 · see citing works

Current results of the screening program at the division of cancer treatment, national cancer institute

GOLDIN, A. S., Venditti, J. M., Macdonald, J. S., Muggia, F. M., Henney, J. E., & DeVita, V. T. (1981) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(81)90027-x · Cited by 209 · see citing works

A Review of Cyclophosphamide.

(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-5-750_2 · Cited by 171 · see citing works

A Review of Cyclophosphamide

Fox, B. W. (1975) · British Journal of Cancer · doi:10.1038/bjc.1975.258 · Cited by 110 · see citing works

Role of angiogenesis in tumor growth and metastasis

Folkman, J. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70065-1 · Cited by 2,862 · see citing works

Angiogenesis: an organizing principle for drug discovery?

Folkman, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2115 · Cited by 2,248 · see citing works

Adipose tissue remodeling and obesity

Sun, K., Kusminski, C. M., & Scherer, P. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45887 · Cited by 1,941 · see citing works

Regulation of Mammalian O ₂ Homeostasis by Hypoxia-Inducible Factor 1

Semenza, G. L. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.551 · Cited by 1,914 · see citing works

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,542 · see citing works

Clinical translation of angiogenesis inhibitors

Kerbel, R. S., & Folkman, J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc905 · Cited by 1,513 · see citing works

The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.

Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,498 · see citing works

Angiogenesis in cancer

Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.213 · Cited by 1,467 · see citing works

The sweet and sour of cancer: glycans as novel therapeutic targets

Fuster, M. M., & Esko, J. D. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1649 · Cited by 1,389 · see citing works

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,387 · see citing works

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234 · see citing works

Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy

Overall, C. M., & Kleifeld, O. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1821 · Cited by 1,212 · see citing works

Angiogenesis

Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209 · see citing works

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Klement, G. L., Baruchel, S., Rak, J. W., Man, S., Clark, K., Hicklin, D. J., Böhlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,166 · see citing works

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed Central · Cited by 1,099 · see citing works

Ten years of anti-vascular endothelial growth factor therapy

Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,040 · see citing works

Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1

Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,014 · see citing works

Tumor Induction of VEGF Promoter Activity in Stromal Cells

Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996 · see citing works

Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice

Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988 · see citing works

Tumor angiogenesis: past, present and the near future

Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 973 · see citing works

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α

Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967 · see citing works

Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts

Lyden, D. C., Young, A. Z., Zagzag, D., Yan, W. X., Gerald, W. L., O'Reilly, R., Bader, B., Hynes, R. O., Zhuang, Y., Manova, K., et al. (1999) · Nature · doi:10.1038/44334 · Cited by 912 · see citing works

Contagious Speculation and a Cure for Cancer: A Nonevent that Made Stock Prices Soar

Huberman, G., & Regev, T. (2001) · The Journal of Finance · doi:10.1111/0022-1082.00330 · Cited by 887 · see citing works

Adipose tissue mass can be regulated through the vasculature

Rupnick, M. A., Panigrahy, D., Zhang, C.-Y., Dallabrida, S. M., Lowell, B. B., Langer, R., & Folkman, M. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162349799 · Cited by 845 · see citing works

Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation

Griffioen, A. W., & Molema, G. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01448-0 · Cited by 843 · see citing works

Antiangiogenic therapy in oncology: current status and future directions

Jayson, G. C., Kerbel, R. S., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 829 · see citing works

Mechanisms of normal and tumor-derived angiogenesis

Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809 · see citing works

Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us

Hlatky, L. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.12.883 · Cited by 780 · see citing works

Angiogenesis: regulators and clinical applications

Liekens, S., De Clercq, E., & Neyts, J. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00529-3 · Cited by 748 · see citing works

Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.

Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 746 · see citing works

Matrix metalloproteinase degradation of extracellular matrix: biological consequences

Shapiro, S. D. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80035-5 · Cited by 714 · see citing works

Angiogenesis Inhibitors Endostatin or TNP-470 Reduce Intimal Neovascularization and Plaque Growth in Apolipoprotein E–Deficient Mice

Moulton, K. S., Heller, E., Konerding, M. A., Flynn, E., Palinski, W., & Folkman, J. (1999) · Circulation · doi:10.1161/01.cir.99.13.1726 · Cited by 688 · see citing works

Vasculogenic Mimicry and Tumor Angiogenesis

Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 682 · see citing works

The mighty mouse: genetically engineered mouse models in cancer drug development

Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 660 · see citing works

Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action

Folkman, J. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.015 · Cited by 657 · see citing works

Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy.

Hahnfeldt, P., Panigrahy, D., Folkman, J., & Hlatky, L. (1999) · PubMed · Cited by 654 · see citing works

Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression

Semenza, G. L. (2000) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230091169186 · Cited by 651 · see citing works

NOTCH Pathway Blockade Depletes CD133-Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts

Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C. M., Zhang, J., Li, Y., Maciaczyk, J., et al. (2009) · Stem Cells · doi:10.1002/stem.254 · Cited by 646 · see citing works

The CCN Family of Angiogenic Regulators: The Integrin Connection

Lau, L. F., & Lam, S. C.-T. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4456 · Cited by 645 · see citing works

Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake

Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · see citing works

Tyrosine kinase – Role and significance in Cancer

Paul, M. K., & Mukhopadhyay, A. K. (2004) · International Journal of Medical Sciences · doi:10.7150/ijms.1.101 · Cited by 627 · see citing works

The molecular biology of cancer

Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 592 · see citing works

Endostatin Induces Endothelial Cell Apoptosis

Dhanabal, M., Ramchandran, R., Waterman, M. J. F., Lu, H. A. J., Knebelmann, B., Segal, M. S., & Sukhatme, V. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11721 · Cited by 582 · see citing works

Acoustic droplet vaporization for therapeutic and diagnostic applications

Kripfgans, O. D., Fowlkes, J. B., Miller, D. L., Eldevik, O. P., & Carson, P. L. (2000) · Ultrasound in Medicine & Biology · doi:10.1016/s0301-5629(00)00262-3 · Cited by 567 · see citing works

Endogenous Inhibitors of Angiogenesis

Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 557 · see citing works

Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?

Lever, A. F., Hole, D. J., Gillis, C. R., McCallum, I. R., McInnes, G. T., MacKinnon, P. L., Meredith, P., Murray, L. S., Reid, J. L., & Robertson, J. W. K. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03228-0 · Cited by 542 · see citing works

Basement membrane proteoglycans: from cellar to ceiling

Iozzo, R. V. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1702 · Cited by 521 · see citing works

Landscaping the Cancer Terrain

Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.280.5366.1036 · Cited by 511 · see citing works

Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1

Arnold, R. S., Shi, J., Murad, E., Whalen, A. M., Sun, C. Q., Polavarapu, R., Parthasarathy, S., Petros, J. A., & Lambeth, J. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101505898 · Cited by 486 · see citing works

Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

Chang, S. S., O’Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D. W., & Gaudin, P. B. (1999) · PubMed · Cited by 465 · see citing works

Cancer as a robust system: implications for anticancer therapy

Kitano, H. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1300 · Cited by 456 · see citing works

Interaction of endostatin with integrins implicated in angiogenesis

Rehn, M., Veikkola, T., Kukk, E., Nakamura, H., Ilmonen, M., Lombardo, C. R., Pihlajaniemi, T. A., Alitalo, K. K., & Vuori, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.3.1024 · Cited by 455 · see citing works

Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism

Lee, A. Y. Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M. H., & Levine, M. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.133 · Cited by 452 · see citing works

Role of Integrins in Cancer: Survey of Expression Patterns

Mizejewski, G. J. (1999) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.1999.d01-122.x · Cited by 449 · see citing works

Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc binding

Yamaguchi, N., Anand‐Apte, B., Lee, M., Sasaki, T., Fukai, N., Shapiro, R., Que, I., Lowik, C., Timpl, R., & Olsen, B. R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.16.4414 · Cited by 440 · see citing works

Vascular Growth Factors and Lymphangiogenesis

Jussila, L., & Alitalo, K. K. (2002) · Physiological Reviews · doi:10.1152/physrev.00005.2002 · Cited by 439 · see citing works

Vasculogenesis and Angiogenesis

Patan, S. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_1 · Cited by 430 · see citing works

Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1

Kim, Y. M., Hwang, S., Kim, Y.-M., Pyun, B., Kim, T., Lee, S., Gho, Y. S., & Kwon, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202771200 · Cited by 429 · see citing works

Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin

O’Reilly, M. S., Pirie-Shepherd, S. R., Lane, W. S., & Folkman, J. (1999) · Science · doi:10.1126/science.285.5435.1926 · Cited by 429 · see citing works

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

Yu, J., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426 · see citing works

Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor

Pettersson, A. F., Nagy, J. A., Brown, L. F., Sundberg, C., Morgan, E. S., Jungles, S., Carter, R., Krieger, J. E., Manseau, E. J., Harvey, V. S., et al. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780013 · Cited by 412 · see citing works

Cell surface tumor endothelial markers are conserved in mice and humans.

Carson-Walter, E. B., Watkins, D. N., Nanda, A., Vogelstein, B., Kinzler, K. W., & Croix, B. S. (2001) · PubMed · Cited by 410 · see citing works

3D tumour models: novel in vitro approaches to cancer studies

Nyga, A., Cheema, U., & Loizidou, M. (2011) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-011-0132-4 · Cited by 403 · see citing works

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400 · see citing works

Angiogenesis Ischemic and Neoplastic Disorders

Semenza, G. L. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152418 · Cited by 386 · see citing works

Receptor tyrosine kinase signalling as a target for cancer intervention strategies.

Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080161 · Cited by 384 · see citing works

Vasculogenesis and Angiogenesis as Mechanisms of Vascular Network Formation, Growth and Remodeling

Patan, S. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006493130855 · Cited by 382 · see citing works

The onset and extent of genomic instability in sporadic colorectal tumor progression

Stoler, D. L., Chen, N., Basik, M., Kahlenberg, M. S., Rodrı́guez-Bigas, M. A., Petrelli, N. J., & Anderson, G. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15121 · Cited by 378 · see citing works

Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

Ma, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0715 · Cited by 369 · see citing works

Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

Gutheil, J. C., Campbell, T. N., Pierce, P. R., Watkins, J. D., Huse, W. D., Bodkin, D., & Cheresh, D. A. (2000) · PubMed · Cited by 369 · see citing works

A cancer therapy resistant to resistance

Kerbel, R. S. (1997) · Nature · doi:10.1038/36978 · Cited by 368 · see citing works

Liposomal paclitaxel formulations

Koudelka, Š., & Tuřánek, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.006 · Cited by 366 · see citing works

Key factors in the acquisition of contrast kinetic data for oncology

Evelhoch, J. L. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3 · Cited by 366 · see citing works

Continuous release of endostatin from microencapsulated engineered cells for tumor therapy

Joki, T., Machluf, M., Atala, A., Zhu, J., Seyfried, N. T., Dunn, I. F., Abe, T., Carroll, R. S., & Black, P. M. (2001) · Nature Biotechnology · doi:10.1038/83481 · Cited by 364 · see citing works

Mathematical modeling of tumor-induced angiogenesis

Mantzaris, N. V., Webb, S., & Othmer, H. G. (2004) · Journal of Mathematical Biology · doi:10.1007/s00285-003-0262-2 · Cited by 360 · see citing works

Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data

Margolin, K. A., Gordon, M. S., Holmgren, E. B., Gaudreault, J., Novotny, W. F., Fyfe, G., Adelman, D. C., Stalter, S., & Breed, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.851 · Cited by 360 · see citing works

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

Xie, C., Wan, X., Quan, H., Zheng, M., Li, F., Li, Y., & Lou, L. (2018) · Cancer Science · doi:10.1111/cas.13536 · Cited by 351 · see citing works

Angiogenesis of Breast Cancer

Schneider, B. P., & Miller, K. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.017 · Cited by 348 · see citing works

Syndecans in inflammation

Götte, M. (2003) · The FASEB Journal · doi:10.1096/fj.02-0739rev · Cited by 346 · see citing works

Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials.

Liu, J., Wang, Y., Akamatsu, Y., Lee, C. C., Stetler, R. A., Lawton, M. T., & Yang, G.-Y. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.11.004 · Cited by 335 · see citing works

Protein N-terminal methionine excision

Giglione, C., Boularot, A., & Meinnel, T. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3466-8 · Cited by 335 · see citing works

The biology of the combretastatins as tumour vascular targeting agents

Tozer, G. M., Kanthou, C., Parkins, C. S., & Hill, S. A. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00211.x · Cited by 331 · see citing works

Initial Stages of Tumor Cell-Induced Angiogenesis: Evaluation Via Skin Window Chambers in Rodent Models

Li, C., Shan, S., Huang, Q., Braun, R. D., Lanzen, J. L., Hu, K., Lin, P. C., & Dewhirst, M. W. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.2.143 · Cited by 331 · see citing works

Structure, function and tissue forms of the C‐terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin

Sasaki, T., Fukai, N., Mann, K., Göhring, W., Olsen, B. R., & Timpl, R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.15.4249 · Cited by 330 · see citing works

Tumor Invasion: Role of Growth Factor-Induced Cell Motility

Wells, A. H. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)61023-4 · Cited by 329 · see citing works

Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved

Kerbel, R. S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.213 · Cited by 324 · see citing works

‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents

Tosetti, F., Ferrari, N., Flora, S. D., & Albini, A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0300rev · Cited by 323 · see citing works

Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase.

Kim, Y. M., Jang, J.-W., Lee, O., Yeon, J.-H., Choi, E.-Y., Kim, K., Lee, S., & Kwon, Y. (2000) · PubMed · Cited by 315 · see citing works

Therapeutic cancer targeting peptides

Aina, O. H., Sroka, T. C., Chen, M., & Lam, K. S. (2002) · Biopolymers · doi:10.1002/bip.10257 · Cited by 313 · see citing works

Drug resistance in cancer: mechanisms and tackling strategies

Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 312 · see citing works

Resveratrol Isolated from Polygonum cuspidatum Root Prevents Tumor Growth and Metastasis to Lung and Tumor-Induced Neovascularization in Lewis Lung Carcinoma-Bearing Mice

Kimura, Y., & Okuda, H. (2001) · Journal of Nutrition · doi:10.1093/jn/131.6.1844 · Cited by 311 · see citing works

Vasostatin, a Calreticulin Fragment, Inhibits Angiogenesis and Suppresses Tumor Growth

Pike, S. E., Yao, L., Jones, K. D., Cherney, B., Appella, E., Sakaguchi, K., Nakhasi, H. L., Teruya‐Feldstein, J., Wirth, P. J., Gupta, G., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2349 · Cited by 310 · see citing works

Inhibition of Human Lung Cancer Cell Growth by the Peroxisome Proliferator-Activated Receptor-γ Agonists through Induction of Apoptosis

Tsubouchi, Y., Sano, H., Kawahito, Y., Mukai, S., Yamada, R., Kohno, M., Inoue, K., Hla, T., & Kondo, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2436 · Cited by 309 · see citing works

Still More Complexity in Mammalian Basement Membranes

Erickson, A., & Couchman, J. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004801001 · Cited by 303 · see citing works

Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., Allen, T. M., Corti, A., & Ponzoni, M. (2003) · PubMed · Cited by 296 · see citing works

Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

Blezinger, P., Wang, J., Gondo, M., Quezada, A., Mehrens, D., French, M., Singhal, A. K., Sullivan, S. M., Rolland, A. P., Ralston, R., et al. (1999) · Nature Biotechnology · doi:10.1038/7895 · Cited by 296 · see citing works

Mechanism and its regulation of tumor-induced angiogenesis

Gupta, M. K. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i6.1144 · Cited by 295 · see citing works

Identification of a peptide blocking vascular endothelial growth factor (VEGF)‐mediated angiogenesis

Tournaire, R., Demangel, C., Malavaud, B. A., Vassy, R., Rouyre, S., Kraemer, M., Plouët, J., Derbin, C., Perret, G. Y., & Mazié, J. C. (2000) · The EMBO Journal · doi:10.1093/emboj/19.7.1525 · Cited by 295 · see citing works

Conditional mouse models of sporadic cancer

Jonkers, J., & Berns, A. J. M. (2002) · Nature reviews. Cancer · doi:10.1038/nrc777 · Cited by 294 · see citing works

Antiangiogenic Activity of Restin, NC10 Domain of Human Collagen XV: Comparison to Endostatin

Ramchandran, R., Dhanabal, M., Volk, R., Waterman, M. J. F., Segal, M. S., Lu, H. A. J., Knebelmann, B., & Sukhatme, V. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0248 · Cited by 290 · see citing works

A flanking attack on cancer

Hanahan, D. (1998) · Nature Medicine · doi:10.1038/nm0198-013 · Cited by 63 · see citing works

Resisting Arrest

(2005) · Science · doi:10.1126/science.310.5751.1091a

Antiangiogenic cancer treatment

Alfred, J. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01435-8

Endostatin: The logic of antiangiogenic therapy

Abdollahi, A., Hlatky, L., & Huber, P. E. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.03.001 · Cited by 117 · see citing works

Anti-angiogenic strategies for cancer therapy (Review)

Benouchan, M., & Colombo, B. (2005) · International Journal of Oncology · doi:10.3892/ijo.27.2.563 · Cited by 29 · see citing works